Spruce Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	96.34	24.49	42.75	157.37	3.92	4.11
Short-Term Investments	0	54.59	46.22	0	0	0
Cash & Cash Equivalents	96.34	79.08	88.97	157.37	3.92	4.11
Cash Growth	21.83%	-11.12%	-43.46%	3910.35%	-4.57%	-
Other Current Assets	5.84	4.53	2.93	3.03	0.73	0.66
Total Current Assets	102.18	83.61	91.9	160.4	4.65	4.77
Property, Plant & Equipment	1.18	1.4	1.48	1.79	0	0
Long-Term Investments	0	0	32.46	0	0	0
Other Long-Term Assets	0.58	0.64	0.65	0.69	0.04	0
Total Long-Term Assets	1.76	2.04	34.59	2.49	0.04	0
Total Assets	103.95	85.65	126.49	162.88	4.69	4.78
Accounts Payable	3.33	1.43	2.82	3.63	1.88	2.3
Deferred Revenue	4.91	0	0	0	0	0
Current Debt	1.62	1.62	0	2.55	1.25	0
Other Current Liabilities	14.6	9.4	6.05	3.58	1.17	0.41
Total Current Liabilities	24.47	12.45	8.87	9.76	4.3	2.71
Long-Term Debt	2.74	4.55	6.17	3.58	3.19	0
Other Long-Term Liabilities	0.24	0.16	0.07	0.12	0.02	0
Total Long-Term Liabilities	2.97	4.72	6.24	3.69	3.21	0
Total Liabilities	27.44	17.16	15.12	13.46	7.52	2.71
Total Debt	4.36	6.18	6.17	6.13	4.45	0
Debt Growth	-29.44%	0.08%	0.69%	37.89%	-	-
Retained Earnings	-197.23	-149.31	-103.13	-60.84	-31.3	-18.21
Comprehensive Income	0	-0.56	-0.18	0	0	0
Shareholders' Equity	76.51	68.49	111.37	149.43	-30.64	-17.8
Net Cash / Debt	91.98	72.9	82.8	151.24	-0.52	4.11
Net Cash / Debt Growth	26.17%	-11.95%	-45.25%	-	-	-
Net Cash Per Share	2.39	3.10	3.54	25.24	-0.68	0.84
Working Capital	77.72	71.16	83.02	150.63	0.35	2.07
Book Value Per Share	1.99	2.91	4.77	24.94	-40.08	-3.62

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).